CLORICROMEN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H26ClNO5
Molecular Weight	395.877
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)COC1=C(Cl)C2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2

InChI

InChIKey=GYNNRVJJLAVVTQ-UHFFFAOYSA-N

InChI=1S/C20H26ClNO5/c1-5-22(6-2)11-10-15-13(4)14-8-9-16(26-12-17(23)25-7-3)18(21)19(14)27-20(15)24/h8-9H,5-7,10-12H2,1-4H3

HIDE SMILES / InChI

Molecular Formula	C20H26ClNO5
Molecular Weight	395.877
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7867874 | https://www.ncbi.nlm.nih.gov/pubmed/16572308 | https://www.ncbi.nlm.nih.gov/pubmed/17593009

Cloricromen a drug that inhibits platelet aggregation in man and in experimental thrombosis. Experiments on rodents have revealed that cloricromene which reduced tumor necrosis factor production, could be useful in the treatment of periodontitis. In addition, it could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable. However, experiments with patients with cerebrovascular occlusive disease didn’t shown any effect of cloricromen on coagulative variables.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
platelet aggregation 80 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7867874 \| https://www.genome.jp/dbget-bin/www_bget?D07139 \| https://www.ncbi.nlm.nih.gov/pubmed/8220889	Inhibitor 8504
NF-kappa B signaling pathway 87 Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322736	Inhibitor 8504

PubMed

Title	Date	PubMed
Protective effects of a coumarin derivative in diabetic rats.	2009-08	19279317
Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.	2006-04	16572308
Cloricromene in endotoxemia: role of NF-kappaB.	2004-08	15322736
Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level.	2001-04-27	11343695

Sample Use Guides

In Vivo Use Guide

Twenty patients with a history of atherothrombotic stroke received cloricromen (100 mg, twice daily) for 30 days in order to evaluate its effects on plasma fibrinogen, antithrombin III, and other variables of the haemostatic system

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:30:06 GMT 2025` Edited by `admin` on `Mon Mar 31 18:30:06 GMT 2025`
Record UNII	B9454PE93C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLORICROMEN

Official Name

English

AD-6

Preferred Name

English

CLORICROMEN [MART.]

Common Name

English

Cloricromen [WHO-DD]

Common Name

English

CLORICROMENE

Common Name

English

ETHYL ((8-CHLORO-3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)ACETATE

Systematic Name

English

cloricromen [INN]

Common Name

English

CLORICROMEN [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QB01AC02